14.84 0.00 (0.00%)
After hours: 5:22PM EDT
|Bid||14.85 x 800|
|Ask||15.85 x 900|
|Day's Range||14.48 - 15.11|
|52 Week Range||8.32 - 20.66|
|Beta (3Y Monthly)||3.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.00|
REDWOOD CITY, Calif., March 19, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 13, 2019, the compensation committee of the company’s.
Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | PositiveShort interest is moderate for CHRS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CHRS are favorable, with net inflows of $1.69 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Coherus BioSciences, Inc. (CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus’ legal and compliance departments, reporting directly to Coherus President and CEO, Denny Lanfear. “Tom brings a passion for our mission, strong leadership skills and deep litigation insights to this critical position,” said Denny Lanfear, President and CEO of Coherus.
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
REDWOOD CITY, Calif., Feb. 28, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year.
REDWOOD CITY, Calif., Feb. 26, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare.
REDWOOD CITY, Calif., Feb. 14, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released.
Each of the asserted Coherus patents is directed to stable formulations of adalimumab. “Coherus recognized early on the central role intellectual property would play in advancing biosimilars to market,” said Denny Lanfear, Chairman, CEO and President of Coherus.
“Biosimilars have an essential role in our healthcare system to restrain cost increases while expanding access for patients,” said Denny Lanfear, Chairman, CEO and President of Coherus. CHS-1420 is among a number of significant biosimilar candidates in Coherus’ pipeline of high-value treatments for patients in need, which include the company’s biosimilar candidates directed to Enbrel®, Lucentis® and Eylea®. The company is currently preparing its biologics license application for CHS-1420 for submission to the U.S. Food and Drug Administration, with anticipated filing in late 2019.
Coherus BioSciences, Inc.'s (NASDAQ:CHRS): Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The US$590m market-cap posted a loss in its most recent financial year of Read More...
Coherus BioSciences, Inc. (CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners. “We are pleased to have the renewed support of HealthCare Royalty Partners,” said Denny Lanfear, President and CEO of Coherus. “This investment reflects our continued confidence in the Coherus leadership team, as well as their ability to execute on their commercial plan,” said Clarke Futch, Managing Partner and Chairman of the Investment Committee of Healthcare Royalty Partners.
REDWOOD CITY, Calif., Jan. 02, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37th annual J.P. Morgan healthcare.